- Home
- IOVA vs BGB Comparison
IOVA vs BGB Comparison
Compare IOVA & BGB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- BGB
- Stock Information
- Founded
- IOVA 2007
- BGB 2012
- Country
- IOVA United States
- BGB United States
- Employees
- IOVA N/A
- BGB N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- BGB Trusts Except Educational Religious and Charitable
- Sector
- IOVA Health Care
- BGB Finance
- Exchange
- IOVA Nasdaq
- BGB Nasdaq
- Market Cap
- IOVA 597.7M
- BGB 538.2M
- IPO Year
- IOVA N/A
- BGB N/A
- Fundamental
- Price
- IOVA $1.75
- BGB $11.94
- Analyst Decision
- IOVA Buy
- BGB
- Analyst Count
- IOVA 10
- BGB 0
- Target Price
- IOVA $12.22
- BGB N/A
- AVG Volume (30 Days)
- IOVA 19.4M
- BGB 154.6K
- Earning Date
- IOVA 05-08-2025
- BGB 01-01-0001
- Dividend Yield
- IOVA N/A
- BGB 9.75%
- EPS Growth
- IOVA N/A
- BGB N/A
- EPS
- IOVA N/A
- BGB N/A
- Revenue
- IOVA $212,679,000.00
- BGB N/A
- Revenue This Year
- IOVA $83.64
- BGB N/A
- Revenue Next Year
- IOVA $70.34
- BGB N/A
- P/E Ratio
- IOVA N/A
- BGB N/A
- Revenue Growth
- IOVA 11070.12
- BGB N/A
- 52 Week Low
- IOVA $1.64
- BGB $10.40
- 52 Week High
- IOVA $12.51
- BGB $11.97
- Technical
- Relative Strength Index (RSI)
- IOVA 33.50
- BGB 56.38
- Support Level
- IOVA $1.70
- BGB $11.78
- Resistance Level
- IOVA $1.87
- BGB $11.93
- Average True Range (ATR)
- IOVA 0.15
- BGB 0.10
- MACD
- IOVA 0.02
- BGB -0.00
- Stochastic Oscillator
- IOVA 27.50
- BGB 74.47
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About BGB Blackstone Strategic Credit 2027 Term Fund of Beneficial Interest
Blackstone Strategic Credit Fund is a closed-end term fund. Its primary investment objective is to seek high current income. The secondary objective of the fund is to seek the preservation of capital. Under normal market conditions, the Fund invests at least 80% of its Managed Assets in senior, secured floating-rate loans. The fund also invest in second-lien loans and high yield bonds and employs financial leverage, which may increase risk to the Fund. The Fund has a limited term and absent shareholder approval to extend the life of the Fund.